Pituitary microadenoma

• Pituitary incidentaloma: a Pituitary Society international consensus guideline statement
• Pituitary surgery in New Zealand: A single neurosurgeon case series of 1,224 operations
• Pituitary and pineal gland metastases from pulmonary neuroendocrine carcinoma: A case report and literature review
• Genetic association of AIP gene variant c.910C>T with pituitary adenomaacromegaly patients of Pakistani origin
• Outcome metrics for primary endoscopic endonasal surgery for low-risk patients with Cushing's disease: an evidence-based position statement from the Registry of Adenomas of the Pituitary and Related Disorders consortium
• Advanced Magnetic Resonance Imaging Techniques for Localization of a Small Thyrotropin-Secreting Pituitary Tumor
• A novel molecular imaging technique using [⁶⁸Ga]Ga-mDesmo PET-CT for localizing tumors in Cushing's disease
• Comprehensive Classification of Surgically Resected Pituitary Neuroendocrine Tumors: Updates From a Single-Institution Experience Based on the WHO 5th Edition

Pituitary microadenoma, its a pituitary neuroendocrine tumor less than 10 mm in diameter.

At the time of diagnosis, 90 % of prolactinomas in women are microadenomas, vs. 60 % for males probably due to gender-specific differences in symptoms resulting in an earlier presentation in females.

Pituitary microadenoma diagnosis.

No consensus exists regarding follow-up recommendations for suspected pituitary microadenoma in children. To address this knowledge gap, Borghammar et al. from Lund investigated the growth potential of pituitary solid and cystic lesions <10 mm in children and evaluated the accuracy of magnetic resonance imaging (MRI) measurements.

Non-functioning pituitary microadenoma in children has small size variations, often below the spatial resolution of the scanners. They suggest lesions <4 mm only for clinical follow-up, lesions 4-6 mm for MRI after 2 years, and ≥7 mm MRI after 1 and 3 years, with clinical follow-up in between. If no progression, further MRI should only be performed after new clinical symptoms or hormonal disturbances. ^{1) 2)}